Elevance Health Inc

Elevance Health Inc(ELV)股票分析

$434.130

-5.948 (-1.37%)收盘时

Loading chart…
最高
450.690
开盘
445.000
成交量加权均价
436.98
成交量
2.47M
市值
124.52B
最低
426.130
成交额
1.08B
企业价值/息税折旧摊销前利润(TTM)
10.72

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses.

AI 分析 of Elevance Health Inc (ELV)

买入

Elevance Health Inc is a strong buy at the current price of $428.26, supported by a forward P/E ratio of 13.68, indicating potential for growth compared to its earnings. The RSI is at 82.08, suggesting the stock is currently overbought, but this momentum can continue in the short term. The company has shown a robust year-to-date change of +20.89%, reflecting strong performance. However, a risk to consider is the hedge fund selling activity, which has increased by 135.25% over the last quarter, indicating some caution among institutional investors.

估值指标

Elevance Health Inc(ELV)当前预期市盈率为 13.68,5 年平均预期市盈率为 13.76。

预期市盈率

合理
5 年均值 P/E
13.76
当前P/E
13.68
高估
15.58
低估
11.94

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
10.29
当前EV/EBITDA
10.72
高估
11.86
低估
8.73

预期市销率

合理
5 年均值 P/S
0.58
当前P/S
0.47
高估
0.72
低估
0.44

Alphio AI 对 ELV 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%ELV

$456.04

情景价格

基

基准

基准 · 50%ELV

$450.58

情景价格

悲

悲观

悲观 · 25%ELV

$379.11

情景价格

持有 ELV 的大户

T

Towers Watson Investment Management Limited

+ 持有ELV

+11.73%

3个月收益率

A

Acadian Asset Management LLC

+ 持有ELV

+9.85%

3个月收益率

V

Vulcan Value Partners, LLC

+ 持有ELV

+9.59%

3个月收益率

T

Trajan Wealth, L.L.C.

+ 持有ELV

+9.30%

3个月收益率

H

Harvest Portfolios Group Inc.

+ 持有ELV

+8.87%

3个月收益率

M

Manulife Asset Management

+ 持有ELV

+8.75%

3个月收益率

事件时间线

2026-10-21 (ET)

16:30:00

Nasdaq Rises on SpaceX Earnings Report

12:30:00

SpaceX Reports First Profit, Tesla Merger Proposal Gains Attention

08:00:00

Elevance Health Appoints Jeff Park as President of Carelon

06:30:00

FY26 Operating Cash Flow Expected at Least $6B

06:30:00

Elevance Health Reports Q3 Revenue of $50.4B, Exceeds Expectations

资讯

ELV 常见问题 —— 由 Alphio AI 解答

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to its Individual, Employer Group risk-based, Employer Group fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program (FEP) members. The Health Benefits segment also offers health products on a full-risk basis. The CarelonRx segment includes its pharmacy services business. CarelonRx markets and offers pharmacy services to its affiliated health plan customers, as well as to external customers outside of the health plans. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services by offering an array of healthcare-related services and capabilities to internal and external customers through its Carelon Health and Carelon Insights businesses. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Elevance Health Inc is a strong buy at the current price of $428.26, supported by a forward P/E ratio of 13.68, indicating potential for growth compared to its earnings. The RSI is at 82.08, suggesting the stock is currently overbought, but this momentum can continue in the short term. The company has shown a robust year-to-date change of +20.89%, reflecting strong performance. However, a risk to consider is the hedge fund selling activity, which has increased by 135.25% over the last quarter, indicating some caution among institutional investors.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易